Clinical trial NCT04034745: Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain
Official title: IIT2018-26 -Hendifar-NETCx: A Descriptive, Multicenter, Single-arm, Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Pancreatic Cancer
Neuroendocrine Tumors
Cachexia; Cancer
Lead sponsor: Cedars-Sinai Medical Center
Sponsor class: OTHER
Collaborators: name: Lexicon Pharmaceuticals
First posted: 2019-07-26
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients will be recruited from Cedars-Sinai Medical Center

Brief summary: This single arm study will evaluate whether Xermelo (telotristat ethyl) associated weight gain is affects lean body mass, dietary intake, and physical and cognitive functioning among neuroendocrine tumor (NET) patients with a history of carcinoid syndrome.

Detailed description: The purpose of this study is to examine the mechanisms of weight gain associated with the drug telotristat ethyl (Xermelo) among patients with a neuroendocrine tumor (NET) with history of carcinoid syndrome. We want to know if taking Xermelo affects patients' lean body mass, quality of life, dietary intake, and physical and cognitive functioning during treatment. A better understanding of the mechanisms of weight gain from Xermelo may allow us to determine whether this drug may be beneficial for treating carcinoid syndrome, cachexia, or weight loss seen in other diseases.

Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years.
* Histopathologically confirmed diagnosis of a metastatic NET.
* Documented history of carcinoid syndrome.
* Currently receiving treatment with long-acting SSAs with a plan to initiate therapy with telotristat-ethyl as per standard of care.
* ECOG performance status 0-1 and/or Karnofsky \>60%.
* Greater than or equal to 3 month life expectancy.
* Ability to understand and the willingness to sign a written informed consent.

Exclusion Criteria:

* Patients experiencing more than 12 watery BMs per day associated with volume contraction, dehydration, or hypotension, or showing evidence of enteric infection.
* History of short bowel syndrome.
* Clinically important baseline elevation in liver function tests.
* Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
* Malignant ascites requiring paracenteses.
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
* Bowel obstruction, partial, or total.
* Pregnancy
* Patients with unresolved grade 3/4 adverse effects of prior therapy at time of enrollment, other than diarrhea

Primary outcomes:
measure: Mean change in lean body mass (measured using DXA Scan) from baseline and after 13 weeks of treatment.
timeFrame: From baseline to 13 weeks after treatment
Secondary outcomes:
measure: Mean change in patient reported outcomes using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) from baseline up to 3 years post treatment.
timeFrame: From baseline to 3 years post treatment
measure: Mean change in patient reported outcomes using the Montreal Cognitive Assessment (MOCA) test from baseline up to 3 years post treatment.
timeFrame: From baseline to 3 years post treatment
measure: Mean change in patient reported outcomes using a stool survey measured from baseline and after 13 weeks of treatment.
timeFrame: From baseline to 13 weeks post-treatment.
measure: Mean change in calories consumed using a 24-hour food diary from baseline and after 13 weeks of treatment.
timeFrame: From baseline to 13 weeks post-treatment
measure: Mean change in daily activity levels (steps) as measured using a wrist-worn fitness tracker (e.g., Fitbit) from baseline and for the duration of the 13 weeks of treatment.
timeFrame: From baseline to 13 weeks post-treatment
measure: Mean change in daily activity levels [stairs (floors) climbed] as measured using a wrist-worn fitness tracker (e.g., Fitbit) from baseline and for the duration of the 13 weeks of treatment.
timeFrame: From baseline to 13 weeks post-treatment
measure: Mean change in daily activity levels (sleep duration) as measured using a wrist-worn fitness tracker (e.g., Fitbit) from baseline and for the duration of the 13 weeks of treatment.
timeFrame: From baseline to 13 weeks post-treatment
measure: Mean change in daily activity levels (heart rate) as measured using a wrist-worn fitness tracker (e.g., Fitbit) from baseline and for the duration of the 13 weeks of treatment.
timeFrame: From baseline to 13 weeks post-treatment
measure: Mean change in daily activity levels (active minutes) as measured using a wrist-worn fitness tracker (e.g., Fitbit) from baseline and for the duration of the 13 weeks of treatment.
timeFrame: From baseline to 13 weeks post-treatment
Other outcomes:
Locations:
Study officials:
affiliation: Cedars-Sinai Medical Center
name: Andrew Hendifar, MD, MPH
role: PRINCIPAL_INVESTIGATOR
References: